Effect of calcium-vitamin D supplementation on metabolic profiles in pregnant women at risk for pre-eclampsia: a randomized placebo-controlled trial.
Effect of calcium-vitamin D supplementation on metabolic profiles in pregnant women at risk for pre-eclampsia: a randomized placebo-controlled trial.
复制标题
DOI：
10.3923/pjbs.2012.316.324
复制
发表时间：
2012-04-01
期刊：
影响因子：
--
通讯作者：
Samimi, Mansooreh
中科院分区：
文献类型：
--
作者：
Asemi, Zatollah;Tabassi, Zohreh;Samimi, Mansooreh
怀孕期间代谢特征的增加与孕产妇和新生儿发病风险的增加有关，并且仍然是一个重大的医学挑战。据我们所知，尚无报告表明补充钙-维生素 D 对有先兆子痫风险的孕妇代谢状况的影响。本研究旨在确定食用钙维生素 D 补充剂对有先兆子痫风险的伊朗孕妇代谢状况的影响。这项随机单盲对照临床试验在 49 名有先兆子痫风险的初产妇中进行，年龄为 18-35 岁，妊娠晚期单胎妊娠。受试者被随机分配服用安慰剂 (n = 25) 或钙维生素 D 补充剂 (n = 24)，为期 9 周。钙维生素 D 补充剂含有 500 毫克碳酸钙和 200 IU 维生素 D3。在基线和干预 9 周后采集空腹血样，以测量空腹血浆血糖 (FPG) 和血脂谱。与安慰剂相比，服用钙-维生素 D 补充剂可降低 FPG 和血清甘油三酯水平（分别为 -9.1 与 0.5 mg dL(-1)；p = 0.03；-11.7 与 49.9 mg dL(-1)；p = 0.001）。钙维生素 D 补充剂和安慰剂对血清总胆固醇、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇水平的影响没有显着差异。安慰剂组的组内差异显示血清甘油三酯水平显着升高（+49.9 mg dL(-1)，p < 0.0001）。总之，有先兆子痫风险的孕妇在怀孕期间服用钙维生素 D 补充剂 9 周，与安慰剂组相比，FPG 和血清甘油三酯水平降低，但不会影响血清总胆固醇、HDL-、LDL-胆固醇水平。
Increased metabolic profiles during pregnancy are associated with an increased risk of maternal and neonatal morbidity and remain a significant medical challenge. To our knowledge, no reports are available indicating the effects of calcium-vitamin D supplementation on metabolic profiles among pregnant women at risk for pre-eclampsia. This study was designed to determine the effects of consumption calcium-vitamin D supplements on metabolic profiles among Iranian pregnant women at risk for pre-eclampsia. This randomized single-blind controlled clinical trial was performed among 49 pregnant women at risk for pre-eclampsia, primigravida, aged 18-35 year old who were carrying singleton pregnancy at their third trimester. Subjects were randomly assigned to consume the placebo (n = 25) or calcium-vitamin D supplements (n = 24) for 9 weeks. Calcium-vitamin D supplements were containing 500 mg carbonate calcium plus 200 IU vitamin D3. Fasting blood samples were taken at baseline and after 9 week intervention to measures of Fasting Plasma Glucose (FPG) and serum lipid profiles. Consumption of calcium-vitamin D supplements resulted in decreased FPG and serum triglycerides levels as compared to the placebo (-9.1 vs. 0.5 mg dL(-1); p = 0.03, -11.7 vs. 49.9 mg dL(-1); p = 0.001, respectively). No significant differences were found comparing calcium-vitamin D supplements and the placebo in terms of their effect on serum total-, HDL-, LDL-cholesterol levels. Within-group differences in the placebo group revealed a significant increase in serum triglycerides levels (+49.9 mg dL(-1), p < 0.0001). In conclusion, consumption of calcium-vitamin D supplements for 9 weeks during pregnancy among pregnant women at risk for pre-eclampsia resulted in decreased FPG and serum triglycerides levels as compared to the placebo group, but could not affect serum total-, HDL-, LDL-cholesterol levels.